Latest Contracts News

Latrobe Magnesium Limited has received a $6.29 million R&D tax rebate from the ATO, using the funds to reduce debt and progress its magnesium production plants in Australia and Malaysia.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Larvotto Resources has initiated underground development at its Hillgrove Antimony-Gold Project, marking a pivotal step toward resuming production with a comprehensive four-year plan.

Lotus Resources has achieved a key milestone at its Kayelekera Uranium Mine with the first high-grade ore delivered to the ROM pad, setting the stage for steady-state production targeted in early 2026. The company has also secured multiple sulphuric acid suppliers and is on track to commission its acid plant to ease supply constraints and reduce costs.

Blue Star Helium has successfully started helium production at its Galactica project in Colorado, positioning itself as America’s newest helium producer with sales targeted for early 2026. The company’s strategic joint venture and low-cost operations underpin a promising growth trajectory amid rising helium and CO₂ demand.

Saunders International has landed a $10.4 million contract to build new water storage infrastructure in South West Sydney, reinforcing its foothold in the growing water infrastructure sector.

Blue Star Helium has successfully started helium production at its Pinon Canyon plant, marking a key milestone as it prepares for commercial sales and expansion in 2026.

Gratifii Limited is set to transform its digital marketing and engagement capabilities through the acquisition of New Zealand’s Mosh Digital and the Future Pass digital wallet platform, backed by a $2.5 million capital raise.

Finbar Group has conditionally acquired a prime South Perth site for $16.5 million, aiming to launch a $350 million apartment development by 2028 and boosting its pipeline to over $1.6 billion.

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.

Aurizon has lodged a proposed ten-year Network Access Undertaking with the Queensland Competition Authority, aiming to secure long-term certainty and enhanced operational incentives for the Central Queensland Coal Network.

Memphasys has inked a five-year supply agreement with Italy’s Centro Fertilita Assistita, marking its first major European contract and setting the stage for broader adoption of its Felix™ sperm isolation system.